Removing total body irradiation (TBI) from conditioning did not degrade efficacy in pediatric and young adult patients with B ...

Race was identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

Elranatamab-bcmm (Elrexfio) demonstrated poorer progression-free survival (PFS) but greater response rates vs eclistamab-cqyv (Tecvayli) in patients with relapsed/refractory multiple myeloma according ...

Nearly one-third of families of children receiving treatment for acute lymphoblastic leukemia (ALL) developed what researchers described as “catastrophic” financial toxicity during therapy, according ...